Company news
Apotex Health Corp. news in 2026
Apotex Health Corp.'s news releases, calls and decks from 2026, newest first.
Apotex launches APO-LINAGLIPTIN™, expanding access to treatment options for Canadians living with type 2 diabetes
November 17, 2026
Apotex launches Axitinib Tablets in the U.S., the first generic version of INLYTA®
November 16, 2026
Apotex to Participate in the Jefferies Global Healthcare Conference in London
November 16, 2026
Apotex Delivers Strong Second Quarter 2027 Results and Raises FY2027 Guidance
November 12, 2026
Apotex to Announce Second Quarter Fiscal 2027 Financial Results and Host Conference Call on November 12, 2026
October 8, 2026
Apotex Health Corp. announces closing of $1,250 million inaugural senior unsecured notes offering
October 5, 2026
Apotex Health Corp. announces $1,250 million inaugural senior unsecured notes offering
September 28, 2026
Apotex Announces First Quarter 2027 Results
August 12, 2026
Apotex Receives Investment Grade Issuer Rating from Morningstar DBRS and Announces Amended & Restated Credit Agreement
July 16, 2026
Apotex to Announce First Quarter Fiscal 2027 Financial Results and Host Conference Call on August 12, 2026
July 9, 2026
Apotex expands U.S. hospital portfolio with launch of generic Infuvite® Adult and Pediatric Injection
July 8, 2026
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
July 1, 2026
Apotex first to receive Health Canada approval for SEVMIA(TM), a generic semaglutide for chronic weight management
June 30, 2026
Apotex Health Corp. announces closing of upsized initial public offering and exercise of Over-Allotment option in full
June 16, 2026
Apotex Health Corp. (APTX) Opens the Market
June 11, 2026
Apotex Health Corp. files final prospectus and announces pricing of upsized initial public offering
June 9, 2026
Calls in 2026
Decks in 2026
- Q2 FY2027 Earnings Presentation
Earnings · 27 slides · November 2026
- Q1 FY2027 Earnings Presentation
Earnings · 24 slides · 2026